{"nctId":"NCT00790335","briefTitle":"Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis","startDateStruct":{"date":"2009-11"},"conditions":["Deep Vein Thrombosis","Venous Thrombosis","Postphlebitic Syndrome","Venous Thromboembolism","Post Thrombotic Syndrome"],"count":692,"armGroups":[{"label":"A-Intervention","type":"EXPERIMENTAL","interventionNames":["Drug: Recombinant tissue plasminogen activator (rt-PA)"]},{"label":"B-Control","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Recombinant tissue plasminogen activator (rt-PA)","otherNames":["rt-PA","recombinant tissue plasminogen activator","Activase","Alteplase"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Symptomatic proximal DVT involving the iliac, common femoral, and/or femoral vein.\n\nExclusion Criteria:\n\n* Age less than 16 years or greater than 75 years.\n* Symptom duration \\> 14 days for the DVT episode in the index leg (i.e., non-acute DVT).\n* In the index leg: established PTS, or previous symptomatic DVT within the last 2 years.\n* In the contralateral (non-index) leg: symptomatic acute DVT a) involving the iliac and/or common femoral vein; or b) for which thrombolysis is planned as part of the initial therapy.\n* Limb-threatening circulatory compromise.\n* Pulmonary embolism with hemodynamic compromise (i.e., hypotension).\n* Inability to tolerate PCDT procedure due to severe dyspnea or acute systemic illness.\n* Allergy, hypersensitivity, or thrombocytopenia from heparin, rt-PA, or iodinated contrast, except for mild-moderate contrast allergies for which steroid pre-medication can be used.\n* Hemoglobin \\< 9.0 mg/dl, INR \\> 1.6 before warfarin was started, or platelets \\< 100,000/ml.\n* Moderate renal impairment in diabetic patients (estimated glomerular filtration rate \\[GFR\\] \\< 60 ml/min) or severe renal impairment in non-diabetic patients (estimated GFR \\< 30 ml/min).\n* Active bleeding, recent (\\< 3 mo) GI bleeding, severe liver dysfunction, bleeding diathesis.\n* Recent (\\< 3 mo) internal eye surgery or hemorrhagic retinopathy; recent (\\< 10 days) major surgery, cataract surgery, trauma, cardiopulmonary resuscitation, obstetrical delivery, or other invasive procedure.\n* History of stroke or intracranial/intraspinal bleed, tumor, vascular malformation, aneurysm.\n* Active cancer (metastatic, progressive, or treated within the last 6 months). Exception: patients with non-melanoma primary skin cancers are eligible to participate in the study.\n* Severe hypertension on repeated readings (systolic \\> 180 mmHg or diastolic \\> 105 mmHg).\n* Pregnant (positive pregnancy test, women of childbearing potential must be tested).\n* Recently (\\< 1 mo) had thrombolysis or is participating in another investigational drug study.\n* Use of a thienopyridine antiplatelet drug (except clopidogrel) in the last 5 days.\n* Life expectancy \\< 2 years or chronic non-ambulatory status.\n* Inability to provide informed consent or to comply with study assessments (e.g. due to cognitive impairment or geographic distance).","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"75 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale)","description":"Patients who experienced one of the following occurrences in the index leg between the 6 month and 24 month post-randomization follow-up visits, inclusive: 1) Villalta score of 5 or greater; 2) leg ulcer; or 3) late endovascular procedure performed to treat severe venous disease. The Villalta scale ranges from 0-33 points, with higher scores being worse.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"171","spread":null}]}]}]},{"type":"SECONDARY","title":"Major Non-post-thrombotic Syndrome Treatment Failure","description":"A major non-post-thrombotic-syndrome treatment failure refers to when any of three events occurred in the index leg: 1) an unplanned endovascular procedure to treat severe venous symptoms within 6 months post-randomization; 2) venous gangrene within 6 months; or 3) an amputation within 24 months.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Any Treatment Failure","description":"Composite of PTS and major non-PTS treatment failure","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"176","spread":null}]}]}]},{"type":"SECONDARY","title":"Moderate-to-severe Post-thrombotic Syndrome","description":"Proportion of patients with Villalta score of 10 or higher at any time between the 6 month and 24 month follow-up visits, inclusive. The Villalta scale ranges from 0-33 points, with higher scores being worse.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]}]},{"type":"SECONDARY","title":"Major Bleeding","description":"Defined as clinically overt bleeding that is associated with a fall in the hemoglobin level of at least 2.0 g/dl, transfusion of ≥ 2 units of red blood cells, or involvement of a critical site (e.g. intracranial, intraspinal).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Major Bleeding","description":"Defined as clinically overt bleeding that was associated with a fall in the hemoglobin level of at least 2.0 g/dl, transfusion of ≥ 2 units of red blood cells, or involvement of a critical site (e.g. intracranial, intraspinal).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Any (Minor + Major) Bleeding","description":"Clinically overt bleeding that occurred through 10 days post-randomization","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Any (Major + Minor) Bleeding","description":"Clinically overt bleeding that occurred within 24 months post-randomization","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Recurrent Venous Thromboembolism","description":"Proportion of patients with symptomatic recurrent venous thromboembolism (including DVT and/or PE)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Recurrent Venous Thromboembolism","description":"Symptomatic recurrent venous thromboembolism (DVT and/or PE)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Death","description":"All-cause mortality","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Death","description":"All-cause mortality","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Severity of Post-thrombotic Syndrome (Villalta)","description":"Mean Villalta scale score at the specified follow-up visit. Villalta score ranges from 0-33 points, with higher scores being worse.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.11","spread":"0.24"},{"groupId":"OG001","value":"4.33","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Severity of Post-thrombotic Syndrome (Villalta)","description":"Mean Villalta scale score at the specified follow-up visit. Villalta score ranges from 0-33 points, with higher scores being worse.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.22","spread":"0.22"},{"groupId":"OG001","value":"4.38","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"Severity of Post-thrombotic Syndrome (Villalta)","description":"Mean Villalta scale score at specified follow-up visit. Villalta score ranges from 0-33 points, with higher scores being worse.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.32","spread":"0.24"},{"groupId":"OG001","value":"4.44","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Severity of Post-thrombotic Syndrome (Villalta)","description":"Mean Villalta scale score at specified follow-up visit. Villalta score ranges from 0-33 points, with higher scores being worse.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.43","spread":"0.28"},{"groupId":"OG001","value":"4.50","spread":"0.29"}]}]}]},{"type":"SECONDARY","title":"Venous Clinical Severity Score","description":"Mean Venous Clinical Severity Score (VCSS) at the specified follow-up visit; range 0-27 (did not use compression item), higher score is worse","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.73","spread":"0.15"},{"groupId":"OG001","value":"2.68","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"Venous Clinical Severity Score","description":"Mean VCSS score at the specified follow-up visit; range 0-27 (did not use compression item)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.80","spread":"0.16"},{"groupId":"OG001","value":"2.37","spread":"0.16"}]}]}]},{"type":"SECONDARY","title":"Venous Clinical Severity Score","description":"Mean VCSS score at the specified follow-up visit; range 0-27 (did not use compression item)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.74","spread":"0.17"},{"groupId":"OG001","value":"2.80","spread":"0.18"}]}]}]},{"type":"SECONDARY","title":"Venous Clinical Severity Score","description":"Mean VCSS score at the specified follow-up visit; range 0-27 (did not use compression item)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.87","spread":"0.18"},{"groupId":"OG001","value":"2.42","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Change in General Quality of Life - Physical","description":"Short-Form-36 Health Survey, Version 2, Physical Component Summary (PCS) Scale. Range of scores 0-100 with higher scores representing better quality of life.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.18","spread":"0.91"},{"groupId":"OG001","value":"10.06","spread":"2.70"}]}]}]},{"type":"SECONDARY","title":"Change in General Quality of Life - Mental","description":"Short-Form-36 Health Survey, Version 2, Mental Component Summary (MCS) Scale. Range of scores 0-100 with higher scores representing better quality of life.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.70","spread":"0.84"},{"groupId":"OG001","value":"2.70","spread":"0.89"}]}]}]},{"type":"SECONDARY","title":"Change in Venous Disease-specific Quality of Life","description":"Venous Insufficiency Epidemiological and Economic Study Quality of Life (VEINES-QOL) questionnaire. Range of scores 0-100 with higher scores representing better quality of life, and higher change scores representing greater improvement from baseline.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.67","spread":"1.71"},{"groupId":"OG001","value":"23.47","spread":"17.31"}]}]}]},{"type":"SECONDARY","title":"Change in Leg Pain Severity","description":"Likert pain scale ranging from 1-7, with higher scores representing a greater intensity of pain","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.62","spread":"0.10"},{"groupId":"OG001","value":"-1.29","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Change in Leg Pain Severity","description":"Likert pain scale ranging from 1-7, with higher scores representing a greater intensity of pain","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.17","spread":"0.11"},{"groupId":"OG001","value":"-1.83","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Change in Leg Circumference","description":"Mean calf circumference measured 10 cm below the tibial tuberosity","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","spread":"0.17"},{"groupId":"OG001","value":"0.27","spread":"0.16"}]}]}]},{"type":"SECONDARY","title":"Change in Leg Circumference","description":"Mean calf circumference measured 10 cm below the tibial tuberosity","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.74","spread":"0.17"},{"groupId":"OG001","value":"-0.28","spread":"0.16"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":109,"n":336},"commonTop":[]}}}